Ketas (Ibudilast) for asthma, stroke and ALS - 100 pcs. 10 mg
Product Code :
Availability : 10
General information on Ketas Ibudilast
Packaging details: 100 tablets of 10 mg.
Manufacturer: Kyorin Pharmaceuticals Co Ltd, Japan
Approved by: Japan Pharmaceutical and Medical Devices Agency. FDA, EMA.
Dosage and Administration: 2 tablets per day, 10 mg. for the treatment of asthma. For the treatment of ALS, the standard method is taking 3 times a day, 10 mg. The dosage may be adjusted by your physician.
Side effects and contraindications: anorexia, headaches, nausea, abdominal pain. Possible liver disfunctions, thrombocytopenia (in rare cases). Not to be used by pregnant and lactating mothers.
What is Ketas (Ibudilast) medicine used for?
Ketas (Ibudilast) is a specialised phosphodiesterase inhibitor used to treat asthma, as well as cerebrovascular disorders (brain and blood vessels), including conditions after a stroke. The medicine is intended to improve general conditions. This medicine is officially approved by the Japan Agency for Pharmaceuticals and Medical Devices and is an officially certified medicine in Japan and an official orphan medicine for ALS in USA and EU.
Who can take Ketas (Ibudilast)?
This medicine is intended for the treatment of asthma, stroke, as well as various vascular and brain diseases. Since 2016, this medicine is a recognized as orphan medicine for the treatment of ALS. All patients should take the medicine with caution and under the supervision of a physician. Special attention when using the medicine should be given to older patients. Note that in the case of asthma treatment, the medicine ketas ibudilas does not stop an asthma attack. In the event of an attack, you must use an inhaler or other means prescribed by the doctor.
How does Ketas (Ibudilast) work?
The medicine is an inhibitor of phosphodiesterase, stopping the interaction of enzymes phosphodiesterase. The medicine increases the supply of oxygen to the lungs, dilates blood vessels. The medicine is a neuroprotector, protecting the brain from pathogenic conditions. The medicine Ketas Ibudilast also has a general anti-inflammatory effect. The mechanism of this medicine’s effects for ALS treatment is not completely clear, but it presumably reduces the speed of development of this disease and has a protective effect on the brain.
In which countries is this medicine officially approved?
The medicine was approved in Japan in May 1989, in 2016, the medicine was approved by the US FDA (link to Ibudalist medicine approval), and in 2017 in the EU (EMA, the link is available here), as an orphan medicine for the treatment of ALS.
Clinical trials of Ketas (Ibudilast).
In Japan, clinical trials of the medicine were conducted using a double-blind study to determine the maximum effectiveness. Both medicine itself, and the dummy-placebo were used for 8 weeks (after a preliminary 8 week follow-up). Clinical trials (link in English is available here) confirmed the effectiveness of the medicine. The medicine showed improvements in 47 cases of the observed, which was much higher in percentage terms than with placebo. Efficacy for asthma is shown in the same study. Clinical research for ALS continues to this day.
Related articles and Reviews.
You can also be interested in the following articles about ALS treatment.